Epigenetic regulation of reprogramming and pluripotency: insights from histone modifications and their implications for cancer stem cell therapies
Frontiers in Cell and Developmental Biology · 03.03.2025 · 13
DOI: 10.3389/fcell.2025.1559183 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 03.03.2025. Verfasst von Woori Bae und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY, United States. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pluripotent stem cells (PSCs) possess the extraordinary capability to differentiate into a variety of cell types. This capability is tightly regulated by epigenetic mechanisms, particularly histone modifications. Moreover, the reprogramming of somatic or fate-committed cells into induced pluripotent stem cells (iPSCs) largely relies on these modifications, such as histone methylation and acetylation of histones. While extensive research has been conducted utilizing mouse models, the significance of histone modifications in human iPSCs is gaining increasing recognition. Recent studies underscore the importance of epigenetic regulators in both the reprogramming process and the regulation of cancer stem cells (CSCs), which are pivotal in tumor initiation and the development of treatment resistance. This review elucidates the dynamic alterations in histone modifications that impact reprogramming and emphasizes the necessity for a balance between activating and repressive marks. These epigenetic marks are influenced by enzymes such as DNA methyltransferases (DNMTs) and histone deacetylases (HDACs). Furthermore, this review explores therapeutic strategies aimed at targeting these epigenetic modifications to enhance treatment efficacy in cancer while advancing the understanding of pluripotency and reprogramming. Despite promising developments in the creation of inhibitors for histone-modifying enzymes, challenges such as selectivity and therapy resistance continue to pose significant hurdles. Therefore, future endeavors must prioritize biomarker-driven approaches and gene-editing technologies to optimize the efficacy of epigenetic therapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY, United States.
- Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
- Department of Medicine, Hematology/Oncology Division, Brody School of Medicine at East Carolina University, Greenville, NC, United States.
Zitieren
APA
Bae, W., Ra, E. A., & Lee, M. H. (2025). Epigenetic regulation of reprogramming and pluripotency: insights from histone modifications and their implications for cancer stem cell therapies. Frontiers in Cell and Developmental Biology, 13. https://doi.org/10.3389/fcell.2025.1559183
Vancouver
Bae W, Ra EA, Lee MH. Epigenetic regulation of reprogramming and pluripotency: insights from histone modifications and their implications for cancer stem cell therapies. Frontiers in Cell and Developmental Biology. 2025;13. doi:10.3389/fcell.2025.1559183
BibTeX
@article{Bae2025,
author = {Bae, Woori and Ra, Eun A and Lee, Myon Hee},
title = {Epigenetic regulation of reprogramming and pluripotency: insights from histone modifications and their implications for cancer stem cell therapies},
journal = {Frontiers in Cell and Developmental Biology},
year = {2025},
volume = {13},
doi = {10.3389/fcell.2025.1559183}
}
EUVIMED